Japanese drug giant Takeda has partnered with Indian vaccine maker Biological E (BE) to manufacture its Dengue vaccine. BE will increase its manufacturing capacity to up to 50 million doses a year, supporting Takeda's goal to produce 100 million doses annually by 2030. The collaboration leverages Takeda's existing facility in Germany and its partnership with IDT Biologika GmbH.
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.